Can food supplements/nutraceuticals prevent cancer?

A review of the literature and clinical studies published in Cancer Therapy Advisor suggests there is currently no evidence that the use of multivitamins or general vitamin and/or antioxidant supplements reduces the risk of developing cancer. With respect to the use of single vitamins or plant supplements, most of the studies conducted so far have […]

read more

High levels of distress among people with kidney cancer

A recent study published in BJU International reports high levels of distress among people with the most common form of kidney cancer, renal cell carcinoma (RCC). Four hundred and fifty (450) people were surveyed online from April to June 2017. Most patients where white (93 %) and more than half were women (56 %). The mean […]

read more

MD Anderson Cancer Center 13th Update on the Management of Genitourinary Malignancies Conference

The MD Anderson Cancer Center (MDACC) 13th Update on the Management of Genitourinary Malignancies Conference took place in Houston, Texas at the end of last week (9-10 November). Kidney cancer highlights from the meeting have been published by UroToday. You can read more online on UroToday below: MDACC 2018: Promising Emerging Systemic Therapies for mRCC MDACC […]

read more

Potential of microRNAs as biomarkers for renal cell carcinoma

A recent review of the knowledge about the potential clinical applications of microRNAs (miRNAs) has been published in the Central European Journal of Urology. Specific biomarkers for the early detection and monitoring of renal cell carcinoma (RCC) would enable early diagnosis of the disease. A non-invasive and sensitive biomarker would also be extremely useful for […]

read more

Microwave ablation for small kidney tumours

A recent retrospective review of the literature and clinical trials, published in the American Journal of Roentgenology (AJR), reports percutaneous (through the skin) microwave ablation (MWA) is a promising treatment strategy for patients with early stage cT1 kidney tumours. The review suggests that more research into the selection of patients for this treatment, and the risks associated […]

read more

Cabozantinib for the treatment of non-clear cell kidney cancer

A recent study published in the European Journal of Cancer shows that cabozantinib produced a clinically meaningful benefit in people with metastatic non-clear cell renal cell carcinoma (RCC), most of whom had disease progression on prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this retrospective study, 30 patients with metastatic non-clear cell […]

read more

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

The combined safety results of two studies with the atezolizumab plus bevacizumab combination were presented at the European Society of Medical Oncology (ESMO) Congress in Munich, Germany last week. The phase 2 IMmotion 150 clinical trial compared the efficacy of the atezolizumab plus bevacizumab combination with atezolizumab alone and sunitinib alone, and then allowed for crossover to […]

read more

ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

The following video interview from Practice Update discusses the promising results from the phase 1b trial of cabozantinib in combination with atezolizumab for metastatic renal cell carcinoma (RCC), the results of which were presented at the European Society of Medical Oncology (ESMO) conference in Munich, Germany last week. Watch the video interview from Practice Update here

read more

Tivozanib expected to be included in European clinical practice guidelines for advanced kidney cancer

Tivozanib is expected to be included as a first-line treatment recommendation for advanced renal cell carcinoma (RCC) in new proposed European guidelines. An outline of the new proposed European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced RCC were presented at the annual ESMO 2018 Congress in Munich, Germany last week. The presentation […]

read more

A type of white blood cell as a potential biomarker to predict response to TKIs and overall survival

A study investigating the prognostic and predictive value of a type of white blood cell called tumour-infiltrating B lymphocytes for tyrosine kinase inhibitor (TKI) therapy in people with metastatic renal cell carcinoma (mRCC) has been published in the journal OncoImmunology recently. These results from the study showed that people with mRCC who were positive for […]

read more
Showing 1 to 10 of 403 results
  TOP